Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DexCom, Inc. (DXCM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q when filed. Dexcom is listed on the Nasdaq Stock Market under the symbol DXCM, and its SEC filings offer detailed information on financial performance, governance, and material events related to its glucose biosensing and continuous glucose monitoring (CGM) business.
Recent Form 8-K filings illustrate how Dexcom uses SEC reports to communicate key developments. For example, the company has filed 8-Ks to furnish quarterly financial results, including revenue by geography and product component, and to describe leadership transitions such as the appointment of Jacob S. Leach as President and Chief Executive Officer and the appointment of Dr. Euan Ashley to the Board of Directors. These filings also document changes in board size, committee assignments, and executive roles.
Dexcom’s periodic reports, including 10-K and 10-Q filings when available, typically contain audited financial statements, discussions of sensor and hardware revenue, descriptions of its CGM and biosensing operations, and risk factor disclosures. Investors can also review sections on research and development spending, capital structure, and non-GAAP performance metrics that the company discusses alongside GAAP results in its earnings-related 8-Ks.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, margin commentary, governance updates, and other material items. Users can also monitor items related to director and executive appointments or departures, and other reportable events under Form 8-K. This page is a central resource for analyzing Dexcom’s regulatory history and for tracking how financial and governance information evolves over time.
DexCom director Bridgette P. Heller reported an open-market sale of 1,012 shares of Common Stock on February 12, 2026 at $68.01 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following this transaction, she beneficially owns 26,019 shares, including 5,046 unvested restricted stock units granted on May 8, 2025 that will vest on the earlier of the one-year anniversary of the grant date or DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
DexCom, Inc. files its annual report describing its continuous glucose monitoring business, led by the G7 and new G7 15 Day systems, Dexcom ONE+ and the Stelo over-the-counter biosensor.
The filing outlines intense competition, extensive global regulatory and privacy obligations, an FDA warning letter on manufacturing and quality systems, and evolving U.S. fraud-and-abuse rules. It also highlights Medicare and commercial coverage, noting that a new competitive bidding program and rental model are expected to reduce Medicare reimbursement for CGM systems starting in 2028.
Dexcom reported strong fourth quarter and full-year 2025 results, with revenue reaching $1.260 billion in Q4, up 13% year over year, and $4.662 billion for 2025, up 16%.
Profitability improved meaningfully. Q4 GAAP operating income rose to $323.0 million (25.6% margin), while full-year GAAP operating income reached $911.8 million (19.6% margin). GAAP net income for 2025 increased to $836.3 million, or $2.09 per diluted share.
The company highlighted the U.S. launch of its Dexcom G7 15 Day system, FDA clearance for Dexcom Smart Basal, and expanded reimbursement in Québec. Dexcom ended 2025 with $2.00 billion in cash, cash equivalents and marketable securities and reiterated 2026 guidance, including revenue of $5.16–$5.25 billion and non-GAAP operating margin of approximately 22–23%.
Dexcom insider Bridgette P. Heller filed a notice of proposed sale under Rule 144 covering 1,012 shares of common stock, with an aggregate market value of
The securities were originally acquired on
Dexcom President and CEO Jacob Steven Leach reported equity compensation activity in the company’s common stock. On January 29, 2026, he received 8,310 shares at $0 upon vesting of previously granted performance-based restricted stock units, reflecting achieved performance goals.
To cover tax withholding on this vesting, 3,058 shares were withheld by Dexcom at $73.36 per share; this withholding is not a sale. After these transactions, Leach directly held 337,051 shares, plus 47,296 shares held indirectly through the Gregg Family Grandchildren's Trust. The direct holdings include 84,537 unvested restricted stock units with various grant and future vesting dates.
EVP and Chief HR Officer Sadie Stern reported routine equity compensation activity. On January 29, 2026, she acquired 7,123 shares of common stock at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023.
The issuer withheld 2,656 shares at $73.36 solely to cover tax obligations related to this vesting, which is not a market sale by Stern. After these transactions, she directly beneficially owned 109,690 shares, including 74,450 unvested restricted stock units scheduled to vest over several dates through March 2028.
DXCM executive vice president and chief financial officer Jereme M. Sylvain reported equity award activity in company common stock. On January 29, 2026, he acquired 7,123 shares at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023 after performance goals were achieved.
On the same date, 2,652 shares were withheld at $73.36 per share to satisfy tax obligations related to this vesting, which the footnotes clarify was not a sale. After these transactions, he directly beneficially owned 123,207 shares, including 83,328 unvested restricted stock units scheduled to vest between March 8, 2026 and March 8, 2028 and 79 shares acquired under the company’s employee stock purchase plan.
DexCom executive Michael Jon Brown, EVP and Chief Legal Officer, reported routine equity activity on January 29, 2026. He received 7,123 shares of common stock at $0 upon vesting of performance-based restricted stock units granted on March 8, 2023 after performance goals were met.
To cover tax withholding on this PSU settlement, 2,653 shares were withheld by the issuer at $73.36 per share, which the filing states does not represent a sale by Brown. After these transactions, he directly owned 98,655 shares, including 86,490 unvested restricted stock units with various vesting schedules through March 8, 2028 and 83 shares acquired under the company’s employee stock purchase plan.
Dexcom Executive Chair Kevin R. Sayer reported equity compensation activity involving the company’s common stock. On January 29, 2026, he received 71,218 shares at $0 upon vesting of performance-based restricted stock units granted on March 9, 2023, after performance conditions were achieved.
On the same date, 34,257 shares at $73.36 were withheld by Dexcom to cover tax obligations related to this PSU settlement, which the filing states does not represent a sale by Sayer. Following these transactions, he directly beneficially owns 408,990 shares of Dexcom common stock.
Included in this amount are 138,091 unvested restricted stock units, consisting of 85,490 RSUs granted on March 8, 2025 that vest through March 8, 2028, 34,461 RSUs granted on March 8, 2024 that vest through March 8, 2027, and 18,140 RSUs granted on March 9, 2023 that vest through March 8, 2026.
Dexcom, Inc. filed a current report describing upcoming preliminary financial disclosures and business updates. President and CEO Jake Leach is scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026, where he will discuss preliminary, unaudited results for the fourth quarter and full fiscal year 2025, as well as an initial financial outlook for fiscal 2026 and other information. These preliminary figures are subject to finalization in connection with Dexcom’s Form 10-K for the year ended December 31, 2025.
The report states that the presentation, together with two related press releases dated January 12, 2026 and January 7, 2026, includes forward-looking statements about revenue, margin guidance and strategic opportunities, which are subject to risks and uncertainties. The press releases are furnished as exhibits and are not deemed filed for liability purposes under the Exchange Act.